The mechanism by which YopP simultaneously inhibits mitogenactivated protein kinase (MAPK) and nuclear factor-jB pathways has been elusive. Ectopic expression of YopP inhibits the activity and ubiquitination of a complex consisting of overexpressed TGF-b-activated kinase 1 (TAK1) and its subunit TAK1-binding protein (TAB)1, but not of MEK kinase 1. YopP, but not the catalytically inactive mutant YopP C172A , also suppresses basal and interleukin-1-inducible activation of endogenous TAK1, TAB1 and TAB2. YopP does not affect the interaction of TAK1, TAB1 and TAB2 but inhibits autophosphorylation of TAK1 at Thr 187 and phosphorylation of TAB1 at Ser 438. Glutathione S-transferase-tagged YopP (GST-YopP) binds to MAPK kinase (MAPKK)4 and TAB1 but not to TAK1 or TAB2 in vitro. Furthermore, YopP in synergy with a previously described negative regulatory feedback loop inhibits TAK1 by MAPKK6-p38-mediated TAB1 phosphorylation. Taken together, these data strongly suggest that YopP binds to TAB1 and directly inhibits TAK1 activity by affecting constitutive TAK1 and TAB1 ubiquitination that is required for autoactivation of TAK1.
INTRODUCTION
Interleukin-1 (IL-1) is a potent proinflammatory cytokine that induces a large number of genes during the inflammatory response (Kracht & Saklatvala, 2002) . Key components of IL-1 signalling pathways, therefore, are attractive targets not only for antiinflammatory therapy but also for anti-inflammatory virulence mechanisms of pathogenic microorganisms. After binding of IL-1 to IL-1 receptor (IL-1R) chains at the cell surface, the adaptor protein tumour necrosis factor (TNF) receptor-associated factor (TRAF)6 is recruited to the cytosolic domains of the activated IL-1R complex. Oligomerized TRAF6 then activates mitogenactivated protein kinase kinase kinase (MAPKKK) protein kinases such as transforming growth factor-b (TGF-b)-activated kinase 1 (TAK1; Ninomiya-Tsuji et al, 1999) or MEKK1 (mitogen-activated extracellular-signal-regulated kinase kinase 1; Xia et al, 2000) . There is compelling evidence derived from experiments using dominant-negative mutants or antisense RNA , inhibitors and RNA interference , and from genetic ablation in mice (Sato et al, 2005) , to suggest that TAK1 is a physiologically relevant MAPKKK in the IL-1 signalling pathway.
Functional TAK1 is a holoenzyme that consists of the catalytic subunit TAK1, the regulatory subunit TAK1-binding protein (TAB)1 and either TAB2 or TAB3 (Takaesu et al, 2000; Ishitani et al, 2003; Cheung et al, 2004) . How endogenous TAK1-TAB complexes are activated is not clear, but recent evidence suggests that Lys 63-linked polyubiquitination of TRAF6 provides a docking surface for the ubiquitin-binding domains of TAB2 and TAB3, thereby recruiting TAK1 to the activated IL-1R complex (Wang et al, 2001; Kanayama et al, 2004) . Then, by unknown mechanisms, TAK1 is activated by autophosphorylation at Thr 187 (Singhirunnusorn et al, 2005) and Ser 192 within the kinase activation loop (Kishimoto et al, 2000) .
On the basis of secondary structure comparisons, the Yersinia enterocolitica virulence factor YopP (called YopJ in Y. pestis and Y. pseudotuberculosis) was predicted to be a cysteine protease that cleaves ubiquitin or small ubiquitin-related modifier (SUMO) conjugates of cellular proteins (Orth et al, 2000) . Y. enterocolitica lacking YopP are less virulent and can be cleared by the host, demonstrating an in vivo immunosuppressive role of YopP (Trulzsch et al, 2004; Viboud & Bliska, 2005) . YopP is encoded on the virulence plasmid pYV. After being injected by means of a type III secretion system into macrophages or other host cells, YopP inhibits nuclear factor-kB (NF-kB) and MAPK signalling simultaneously (Ruckdeschel et al, 1997 (Ruckdeschel et al, , 1998 Orth et al, 1999; Viboud & Bliska, 2005) . YopP binds to and deubiquitinates IkB kinase-b (IKKb) when coexpressed with IKKb together with epitope-tagged ubiquitin (Carter et al, 2003) . YopP also interacts with MAPK kinase (MAPKK1, MAPKK2, MAPKK3/4 and MAPKK5 (Orth et al, 2000) . However, there is no evidence that MAPKKs require ubiquitin or SUMO conjugates for activation. Hence, the mechanism by which YopP suppresses several proinflammatory signalling pathways simultaneously has been elusive (Juris et al, 2002; Navarro et al, 2005) . Considering the importance of TAK1 for activation of NF-kB, c-Jun amino-terminal kinase (JNK) and p38 MAPK in the IL-1 signalling pathway, we set up experiments to explore whether YopP acts at the level of the TAK1 complex. We report here that YopP binds to TAB1 and inhibits endogenous TAK1 activity.
RESULTS AND DISCUSSION
To test the hypothesis of whether YopP affects host cell signalling at the level of the MAPKKK MEKK1 or TAK1, we ectopically expressed a green fluorescent protein (GFP)-tagged YopP fusion protein (GFP-YopP) in HEK293IL-1R (human embryonic kidney 293 stably expressing the IL-1 receptor) cells. GFP-YopP was expressed at a low level, but could be detected after immunoprecipitation ( Fig 1A) . Induction of the chemokine IL-8 requires parallel activation of NF-kB and of at least two MAPK pathways (Hoffmann et al, 2002) . GFP-YopP strongly suppressed transcription of an IL-8 promoter-driven luciferase reporter gene that was activated by: TAK1 coexpressed with its regulatory subunit TAB1; a truncated highly active form of MEKK1, MEKK1D; or, IL-1 treatment (Fig 1B) . Interestingly, MEKK1D immunoprecipitated from YopP-transfected cells was still enzymatically active ( Fig 1C,  lanes 1,2) . Hence, suppression of MEKK1D-dependent IL-8 transcription by YopP, as shown in Fig 1B, must occur by inhibition of NF-kB and MAPK signalling downstream from MEKK1D, confirming the observation by Orth et al (1999) . By contrast, the activity of TAK1 immunoprecipitated from YopPtransfected cells was strongly suppressed (Fig 1C, lanes 3,4) . In vitro phosphorylation of co-immunoprecipitated GFP-TAB1 by GFP-TAK1 was abolished, whereas autophosphorylation of GFP-TAK1 was significantly reduced, and 32 P-GFP-TAK1 showed a faster mobility on SDS-polyacrylamide gel electrophoresis (SDS-PAGE) in vitro ( Fig 1C, lanes 3,4) . As assessed by a specific in vivo ubiquitination assay, overexpressed TAK1 and TAB1 were covalently linked to coexpressed histidine (His)-tagged ubiquitin chains (Fig 1D) . TAK1-ubiquitin conjugates appeared as smears on SDS-PAGE, which is compatible with TAK1 polyubiquitination, whereas ubiquitinated TAB1 appeared as a more distinct band, suggesting that TAB1 might be primarily monoubiquitinated (Fig 1D) . Importantly, coexpression of YopP prevented ubiquitination of TAK1 and TAB1 in intact cells. By contrast, ubiquitination of MEKK1D was not affected by YopP (Fig 1D) . Collectively, the experiments shown in Fig 1 suggested that, in addition to the previously observed mechanisms targeting inhibitor of nuclear factor-kB kinase b (IKKb) and MAPKK, YopP can also affect specific MAPKKKs such as TAK1 by directly (or indirectly) removing ubiquitin chains that are required for activation.
To confirm a role of YopP in the activation mechanism of the endogenous TAK1 kinase complex, we immunoprecipitated it by using TAB2 antibodies and analysed its composition and enzymatic activity by using western blotting and in vitro kinase assays. Constitutive as well as IL-1-induced kinase activity of TAK1 was strongly suppressed after YopP transfection, as shown by phosphorylation of recombinant MAPKK6 and by autophosphorylation of TAK1 at Thr 187 (Fig 2A) . YopP did not affect the interaction of TAK1 with TAB1 and TAB2 (Fig 2B) . A YopP mutant with a point mutation in the catalytic triad of the protease domain (Cys172Ala) failed to suppress TAK1-induced activation of IL-8 transcription ( supplementary Fig 1 online) , TAK1 kinase activity (Fig 3A) or TAK1-mediated phosphorylation of co-precipitated TAB1 and TAB2 ( Fig 3A) . Furthermore, basal and IL-1-inducible TAK1 activity was suppressed in cells infected with wild-type Y. enterocolitica, but not in cells infected with a strain in which YopP was replaced by an allele encoding the Cys172Ala mutant ( Fig 3B) . Hence, the results shown in Figs 2,3 suggest that in intact cells catalytically active YopP directly inhibits endogenous TAK1 kinase activity. As a consequence, YopP suppresses phosphorylation of TAB1, TAB2, NF-kB, JNK and p38 (as shown in supplementary Fig 2 online) .
So far, the only known negative regulatory mechanism that affects TAK1 is an autoregulatory feedback loop by which p38 MAPK-mediated phosphorylation of TAB1 dampens constitutive activity of the TAK1-TAB1 complex in unstimulated cells and shuts off IL-1-stimulated TAK1 kinase activity after an initial activation phase (Cheung et al, 2003) . As shown in Fig Fig 4C) . This suggests that TAB1 form 2 results from constitutive phosphorylation by p38 MAPK, possibly at Ser 438, which is the only known constitutively phosphorylated amino acid (Cheung et al, 2003) . As shown in Fig 4A, B, lane 3, in IL-1-stimulated cells, TAB1 form 2 was shifted to a form with slower mobility (designated form 1), indicating that IL-1 induces further phosphorylation of TAB1, possibly at the other two p38 MAPK phosphorylation sites Ser 423 and Thr 431 (Cheung et al, 2003) . To test this hypothesis, in haemagglutinin-tagged TAB1 (HA-TAB1), all three sites were mutated to alanine, and the mobility of TAB1 was analysed in co-transfection experiments with YopP or TAK1. As shown in Fig 4D, (Fig 4D, lanes 6,9,12 ). Inhibition of p38 MAPK by SB203580 increased IL-1-induced autophosphorylation of TAK1 at Thr 187 (Fig 4B, lane 4) , whereas YopP co-transfection suppressed IL-1-induced phosphorylation of Thr 187 (Fig 4A, lane 4) . Hence, although both YopP and SB203580 affect basal TAB1 phosphorylation at Ser 438, they affect activation of TAK1 differently. (B) HEK293IL-1R cells were transiently transfected with pUHC13-3-IL-8pr and expression vectors for GFP-YopP, GFP-TAK1, GFP-TAB1 or MEKK1D-BFP, as indicated. A vector encoding GFP was used to adjust the total amount of DNA in all samples. After 24 h, cells were treated with IL-1 (10 ng/ml) for 5 h (lanes 7,8) or were left untreated. Thereafter, cells were lysed and luciferase activity was determined. Mean values7s.e.m. from two experiments are shown. Aliquots of the lysates were analysed by western blotting for expression of the transfected proteins and for endogenous TAK1 using anti-GFP or anti-TAK1 (M-579) antibodies, respectively. (C) Cells were transfected as in (B). After 24 h, GFP-TAK1 þ GFP-TAB1 or MEKK1D-BFP were immunoprecipitated with anti-GFP antibodies from whole-cell lysates and their activity was measured by in vitro kinase assay using His-MKK6 as substrate. In lane 5, the kinase reaction was performed, omitting immunoprecipitated proteins, as a control for autophosphorylation of His-MKK6. (D) HEK293IL-1R cells were transfected with expression vectors for HA-TAK1, MEKK1D-BFP, Myc-TAB1, GFP-YopP and His-ubiquitin. After 24 h, cells were lysed in denaturing buffer, precipitated and redissolved in sample buffer (Input). His-tagged ubiquitinated proteins were purified by adsorption to Ni 2 þ -NTA agarose (Ni 2 þ -pulldown). Proteins were separated by SDS-polyacrylamide gel electrophoresis and detected in the input sample and in the bound fraction by western blotting using antibodies against HA, GFP or Myc. Ub n indicates the polyubiquitinated forms of HA-TAK1 and MEKK1D-BFP. Numbers indicate the relative amounts of antigen in the input samples and in the bound fractions compared with the control samples. BFP, blue fluorescent protein; GFP, green fluorescent protein; HA, haemagglutinin; His, histidine; IL-1, interleukin-1; MEKK1, MEK kinase 1; MKK6, MAPK kinase 6; TAB1, TAK1-binding protein 1; TAK1, TGF-b-activated kinase 1; TGF-b, transforming growth factor-b, YopP, Yersinia outer membrane protein P.
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A. Thiefes et al We used this information to design further experiments to assess whether YopP acts at the level of TAK1 or downstream from TAK1 by affecting the p38-TAB1 feedback mechanism.
When HA-TAK1 was co-purified with Myc-TAB1, strong TAK1 kinase activity and autophosphorylation at Thr 187 could be detected in vitro (Fig 4E, lane 5) . Coexpression of YopP increased the mobility of Myc-TAB1, resulting in form 3 (Fig 4E, lanes 2,6) , and inhibited HA-TAK1 (Fig 4E, lane 6) . By contrast, coexpression of an active form of MAPKK6 and of p38 MAPK decreased the mobility of Myc-TAB1, resulting in form 1 (Fig 4E, lanes 3,7) , and inhibited HA-TAK1 (Fig 4E, lane 7) . Moreover, MAPKK6-p38 MAPK in synergy with the coexpressed YopP suppressed TAK1 Inhibition of TAK1 by the Y. enterocolitica effector YopP A. Thiefes et al kinase activity (Fig 4E, lane 8) . This clearly shows that YopP or MAPKK6-p38 MAPK inhibits TAK1 by two different mechanisms. MAPKK6-p38 indirectly inhibits TAK1 by promoting the hyperphosphorylated form 1 of TAB1, which was previously found to inhibit TAK1 (Cheung et al, 2003) . By contrast, YopP inhibits autophosphorylation of TAK1 at Thr 187 (Figs 2A,3A,4) , which indirectly results in the suppression of TAK1-MAPKK4/6-p38-mediated TAB1 phosphorylation. YopP also inhibits monoubiquitination of TAB1 (Fig 1D) , the contribution of which to TAK1 activation still needs to be clarified. However, TAB1 might be important in recruiting YopP to the TAK1 complex as glutathione S-transferase (GST)-YopP bound to cellularly expressed TAB1, but not to TAK1 or TAB2 in vitro (Fig 5) . In these assays, GST-YopP also bound to MAPKK4 (Fig 5) , as described previously (Orth et al, 1999) .
Speculation
While our manuscript was being reviewed, Haase et al (2005) reported that, in Yersinia-infected cells, YopP affects the recruitment of TAK1 by TAB2 and thereby inhibits TAK1. Thus, although our data support the observation that YopP inhibits TAK1, we propose a different mechanism of inhibition on the basis of the observation that it is the enzymatic activity rather than the interaction of TAK1-TAB1-TAB2 that is targeted by YopP.
In addition, in contrast to recent reports on overexpressed TRAF6 (Haase et al, 2005; Zhou et al, 2005) , we did not find that Transfections and reporter gene assays. Calcium phosphate transfections and reporter gene assays were performed as described previously (Hoffmann et al, 2005) . For the experiments shown in Figs 2-5A, cells (4.5 Â 10 5 cells per six wells) were transfected with 3 mg of expression plasmid for GFP-YopP or empty vector and 6 ml of Roti s -Fect (Roth, Karlsruhe, Germany). After 24 h, cells were treated as described in the figure legends. Cell lysis, immunoprecipitations and in vitro kinase assays. Cell lysis, immunoprecipitations, radioactive kinase assays were performed essentially as described by Cheung et al (2003) and as given in the supplementary information online.
In vivo ubiquitination assays. Cells were transfected with expression vectors for HA-TAK1, Myc-TAB1 or His (6) -ubiquitin and GFP-YopP. Cells were lysed in denaturing buffer and proteins bound to Ni 2 þ -NTA agarose were detected by western blotting. GST pulldown assays. Cells were transfected with expression vectors for HA-TAK1, Myc-TAB1, T7-TAB2 or Myc-MAPKK4. Proteins bound to immobilized GST or to GST-YopP were detected by western blotting. Western blotting. Western blotting was performed as described previously (Hoffmann et al, 2005) . Quantification of signals was achieved using ImageJ 1.36b (http://rsb.info.nih.gov/ij). For detailed information on methods and materials, see the supplementary information online. Supplementary information is available at EMBO reports online (http://www.emboreports.org). Inhibition of TAK1 by the Y. enterocolitica effector YopP A. Thiefes et al
